AstraZeneca's TAGRISSO-Savolitinib Combo Shows Survival Gains in MET-Driven Lung Cancer
Event summary
- AstraZeneca's SAFFRON Phase III trial showed TAGRISSO plus savolitinib improved progression-free and overall survival in MET-driven EGFR-mutated lung cancer.
- The trial enrolled 338 patients across 29 countries, with primary endpoint being progression-free survival.
- Savolitinib is jointly developed by AstraZeneca and HUTCHMED, with AstraZeneca handling commercialization.
- The combination is already approved in China for locally advanced or metastatic EGFRm NSCLC with MET amplification.
- Safety profile was consistent with known profiles of each medicine, with no new safety findings.
The big picture
AstraZeneca's positive SAFFRON trial results reinforce its leadership in EGFR-mutated lung cancer, addressing a critical unmet need for patients with MET-driven resistance. The combination of TAGRISSO and savolitinib offers a biomarker-directed, all-oral treatment option, potentially reshaping the standard of care in this setting. This strategic advance aligns with AstraZeneca's broader oncology strategy to improve patient outcomes across multiple stages and lines of therapy.
What we're watching
- Regulatory Pathways
- The pace at which global regulatory authorities will approve the TAGRISSO-savolitinib combination for broader use, following the positive SAFFRON trial results.
- Commercial Strategy
- How AstraZeneca and HUTCHMED will position this combination therapy in the competitive landscape of targeted lung cancer treatments.
- Market Adoption
- Whether oncologists will widely adopt MET testing to identify patients suitable for this targeted combination therapy.
Related topics